print this page

Bruce Waslick, MD

Psychiatry Department   Image  
Child and Adolescent Psychiatry Division
  • Associate Professor of Psychiatry, Tufts University School of Medicine
759 Chestnut Street, WG703
Springfield, MA 01199
  • Child Psychiatry Fellowship
    Columbia University
    New York, NY
  • Psychiatry Residency
    New England Medical Center/Tufts University School of Medicine
    Boston, MA
Areas of Interest
  • Child psychiatry
  • Pediatric mood disorders
  • Pediatric psychopharmacology
  • Compton SN, Walkup JT, Albano AM, Piacentini JC, Birmaher B, Sherrill JT, Ginsburg GS, Rynn MA, McCracken JT, Waslick BD, Iyengar S, Kendall PC, March JS. Child/Adolescent Anxiety Multimodal Study (CAMS): Rationale, design and methods. Child Adolesc Psychiatry Ment Health 2010;4:Article 1.
  • Vitiello B, Waslick B. Pharmacotherapy for children and adolescent with anxiety disorders. Psychiatr Ann 2010;40:185-191.
  • Waslick BD, Brooks B, Burns J, Sarvet B. Depression: an Overview, in Handbook of Adolescent Depression in Primary Care, edited by Jensen P, Zuckerbrot R, Cheung A. In press
  • Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, Sertraline, or a combination in childhood anxiety. N Eng J Med, 2008;359:2753-2766
  • Emslie GJ, Waslick BD, Weller EB et al. Antidepressant management in the context of suicidal ideation. JAACAP, 2007; 46:1222-1225
  • Waslick BD. Treatment of Depression in Adolescents: TADS Results and Future Directions - Psychiatric Times. Psychiatric Times, 2007; 24
  • Waslick BD. Benefits and harms of pediatric antidepressant medications (letter). JAMA, 2007; 298: 626
  • Zuckerbrot A, Cheung A, Jensen P, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, Assessment, and Initial Management. Pediatrics, Nov 2007; 120: e1299 - e1312
  • Cheung A, Zuckerbrot R, Jensen P, et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and Ongoing Management. Pediatrics. 2007 120: e1313 - e1326
  • TADS Cooperative Group. The Treatment for Adolescents with Depression Study (TADS): Long-Term Effectiveness and Safety Outcomes. Archives of General Psychiatry, 2007; 64: 1132 – 1143
  • Kennard BD, Silva S, Vitiello B et al. Remission and residual symptoms after acute treatment of adolescents with major depressive disorder. JAACAP, 2006; 45:1404-1411
  • Kratochvil C, Emslie G, Silva S et al. Acute time to response in the treatment for adolescents with depression study (TADS). JAACAP, 2006; 45:1412-1418
  • Vitiello B, Rhode P, Silva S, Wells K, Casat C, Waslick BD, Simmons A et al. Functioning and quality of life in the treatment for adolescents with depression study (TADS). JAACAP, 2006; 45:1419-1428
  • Curry JF, Rohde P, Silva S, Vitiello B, Simons A, et al. Predictors and moderators of acute outcome in the treatment for adolescents with depression study (TADS). JAACAP, 2006; 45:1427-1439
  • Emslie G, Kratochvil CJ, Vitiello B, March J, Weller E, Waslick BD, Casat C, et al. Treatment for adolescents with depression (TADS):  safety results.  JAACAP, 2006; 45:1440-1455
  • Waslick BD Oxcarbazepine and pediatric bipolar disorder (letter). Am J Psychiatry 2006; 163: 2195
  • Bolfek A, Jankowski JJ, Waslick BD, Summergrad P. Adolescent psychopharmacology: drugs for mood disorders. Adolescent Medicine Clinics. 2006; 17(3):789-808
  • Waslick BD, Psychopharmacology interventions for pediatric anxiety disorders: a research update. Child and Adolescent Psychiatry Clinics of North America. 2006
  • Waslick BD, Greenhill LL, Attention-deficit hyperactivity disorder.  In M. Dulcan, Essentials of Child and Adolescent Psychiatry, American Psychiatric Press, Inc. 2006
  • Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller E, Burke WJ, March J, SSRIs in pediatric depression: is the balance between benefits and harms favorable?  Journal of Child and Adolescent Psychopharmacology. 2006
  • 2006-2010, Site Principal Investigator, An Open-label, Prospective Cohort Study of Antidepressants in Children and Adolescents with Anxiety Disorders, Depressive Disorders, Eating Disorder, or Obsessive-Compulsive Disorder, Duke University
  • 2007-2010, Principal Investigator, A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Study of the Safety and Efficacy of Emsam® in Adolescents with Major Depression, Somerset Pharmaceuticals
  • 2008-2011, Principal Investigator, The Evaluation of LAMICTAL as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, GlaxoSmithKline
  • 2009, Principal Investigator, A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents Aged 6-17 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD), Shire Development, Inc